Skip to content
HowShorted

REATA PHARMACEUTICALS INC short interest in 2020

In 2020, REATA PHARMACEUTICALS INC's disclosed short interest ran from 10.08% of shares outstanding on 15 Jan 2020 to 9.22% on 31 Dec 2020, a change of -0.86 percentage points. The year's high was 10.74% on 15 Jun 2020 and its low 8.82% on 14 Feb 2020, averaging 9.84% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.39 days on 31 Jul 2020. Full history: REATA PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for REATA PHARMACEUTICALS INC in 2020

2020 in figures

Start of year
10.08% (15 Jan 2020)
End of year
9.22% (31 Dec 2020)
Change
-0.86 pp
High
10.74% (15 Jun 2020)
Low
8.82% (14 Feb 2020)
Average
9.84%
Highest days to cover
26.39 (31 Jul 2020)
SEC filings marked
8

Every report in 2020

REATA PHARMACEUTICALS INC short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202010.08%10.00
31 Jan 20209.69%12.19
14 Feb 20208.82%6.72
28 Feb 20208.88%7.3110-K filed, results (8-K)
13 Mar 20208.97%7.75
31 Mar 20209.38%7.36
15 Apr 20209.43%11.32
30 Apr 20209.79%13.79
15 May 202010.21%13.8610-Q filed, results (8-K)
29 May 202010.49%18.93
15 Jun 202010.74%7.20
30 Jun 202010.69%6.27
15 Jul 202010.67%16.51
31 Jul 202010.34%26.39
14 Aug 202010.02%4.5910-Q filed, results (8-K)
31 Aug 20209.97%14.00
15 Sep 202010.51%14.61
30 Sep 202010.54%9.17
15 Oct 202010.14%21.76
30 Oct 20209.28%22.52
13 Nov 20209.09%7.8310-Q filed, results (8-K)
30 Nov 20209.48%12.30
15 Dec 20209.80%6.39
31 Dec 20209.22%10.26

See also: REATA PHARMACEUTICALS INC's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.